Drugs / WT2725
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01621542 | Jul 2012 → May 2017 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT2725 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01621542 ↗ |
| Modality | Vaccine | “WT2725 is a Wilms' tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1+ tumors in human leukocyte antigen...” PMID 34785698 ↗ Nov 2021 |
| Target | WT1 | “WT2725 is a Wilms' tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1+ tumors in human leukocyte antigen...” PMID 34785698 ↗ Nov 2021 |